- Company
- Dexeryl for atopic dermatitis lands in Korea
- by Oct 27, 2022 05:52am
- Pierre Fabre Korea announced that it had launched its medical device cream ‘Dexeryl’ in Korea on the 26th. Dexeryl is an MD cream that represents the 60-year-old French pharmaceutical company, Pierre Fabre. It is used to treat dryness of the skin and symptoms from skin conditions, such as atopic dermatitis, pruritus, diabetic foot dise
- Company
- The unfinished aftershocks of COVID-19
- by Chon, Seung-Hyun Oct 26, 2022 05:50am
- The market for outpatient prescription drugs was the largest ever. This year, the prescription market has grown significantly due to the expansion of prescriptions such as cold medicine due to the rapid increase in the number of COVID-19 confirmed patients. The size of Expectant prescriptions used to relieve COVID-19 symptoms has more than doubl
- Company
- First TYK2 inhibitor Sotyktu will enter Korean market
- by Eo, Yun-Ho Oct 26, 2022 05:50am
- The oral TYK2 inhibitor for psoriasis will soon be introduced to Korea. According to industry sources, BMS Korea applied for domestic marketing authorization for its tyrosine kinase 2 (TYK2) inhibitor ‘Sotyktu (deucravacitinib) in Korea. The drug was approved for the treatment of adults with moderate-to-severe plaque psoriasis who are
- Company
- Xarelto sales fall 30% due to generics and price cuts
- by Oct 26, 2022 05:50am
- The quarterly prescription of new oral anticoagulants (NOAC) containing rivaroxaban, which had reached KRW 15 billion, has shrunk to KRW 13 billion. This decrease is interpreted to be reflected by the price cut of Bayer’s original ‘Xarelto.’ Its generics that entered the market 1 year ago have been starting to slowly increase their share in t
- Company
- Genuone challenges Trajenta’s non-listed patent...Why?
- by Kim, Jin-Gu Oct 25, 2022 05:46am
- Genuone Sciences has challenged the unlisted patents of Trajenta (linagliptin). Industry interpretations are that the move is the company’s strategy to remove uncertainties in releasing generic versions of Trajenta and to additionally attract CMO deals” According to industry sources on the 24th, Genuone Sciences filed a trial to co
- Company
- Cibinqo lands in general hospitals in Korea
- by Eo, Yun-Ho Oct 25, 2022 05:46am
- Pfizer’s second Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib) has landed and may be prescribed at general hospitals in Korea. According to industry sources, Pfizer Korea’s new JAK1 inhibitor drug (abrocitinib) has passed the drug committee (DC) reviews of the ‘Big 5 tertiary hospitals’ of Korea including the Seoul National Uni
- Company
- GSK has signed a sales contract with GC Pharma & Kwang Dong
- by Eo, Yun-Ho Oct 25, 2022 05:46am
- GSK has signed a joint sales contract with two domestic companies, GC Pharma and Kwang Dong, to sell the shingles vaccine Shingrix. GSK Korea announced on the 24th that it signed a Co-Promotion and Distribution Partnership for Shingrix's domestic sales and marketing on the 21st. Through this partnership, GC Pharma and Kwang Dong will joint
- Company
- Lyumjev can be prescribed in general hospitals
- by Eo, Yun-Ho Oct 24, 2022 06:08am
- The new fast-acting insulin ‘Lyumjev’ can now be prescribed at general hospitals in Korea. According to industry sources, Lilly Korea’s ‘Lyumjev (insulin lispro)’ has passed the drug committee (DC) reviews of various medical institutions including the Samsung Medical Center. Lyumjev, which was approved in Korea in December last y
- Company
- Will Onureg, an acute leukemia maintenance drug be listed?
- by Eo, Yun-Ho Oct 24, 2022 06:08am
- Attention is focusing on whether Onureg will be able to be listed on the insurance benefit list. According to related industries, Onureg of BMS Pharmaceutical Korea is expected to be submitted to the HIRA Cancer Disease Review Committee on the 2nd of next month. Onureg is the only oral maintenance of acute myeloid leukemia. It was approved in
- Company
- Lucentis biosimilar of Chong Kun Dang gets domestic approval
- by Chon, Seung-Hyun Oct 24, 2022 06:08am
- Chong Kun Dang succeeded in commercializing its second biosimilar. Chong Kun Dang announced on the 20th that it has received approval from the Ministry of Food and Drug Safety for domestic items of the "Lucentis" biosimilar. The indication for "treatment of neovascular (habitual) age-related macular degeneration" has been approved. Lucenti
